diflunisal
Selected indexed studies
- Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis. (Ann Clin Transl Neurol, 2024) [PMID:39096004]
- The use of diflunisal for transthyretin cardiac amyloidosis: a review. (Heart Fail Rev, 2022) [PMID:34272629]
- Diflunisal-loaded poly(propylene sulfide) nanoparticles decrease S. aureus-mediated bone destruction during osteomyelitis. (J Orthop Res, 2021) [PMID:33300149]
_Worker-drafted node — pending editorial review._
Connections
diflunisal is a side effect of
Sources
- Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis. (2024) pubmed
- The use of diflunisal for transthyretin cardiac amyloidosis: a review. (2022) pubmed
- Diflunisal-loaded poly(propylene sulfide) nanoparticles decrease S. aureus-mediated bone destruction during osteomyelitis. (2021) pubmed
- Single dose oral diflunisal for acute postoperative pain in adults. (2010) pubmed
- Diflunisal: a review of its pharmacological properties and therapeutic use in pain and musculoskeletal strains and sprains and pain in osteoarthritis. (1980) pubmed
- Diflunisal--a long-acting non-steroidal anti-inflammatory drug. A review of its pharmacology and effectiveness in management of postoperative dental pain. (1993) pubmed
- [Diflunisal]. (1982) pubmed
- Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway. (2021) pubmed
- Diflunisal targets the HMGB1/CXCL12 heterocomplex and blocks immune cell recruitment. (2019) pubmed
- Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. (2015) pubmed